Crossmark

RF – Tildrakizumab 200 mg. Is Double Dosing Really a Window of Opportunity?

Crossref DOI link: https://doi.org/10.1016/j.ad.2025.104539

Published Print: 2026-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Llamas-Segura, C. https://orcid.org/0000-0002-5334-2229
Cebolla-Verdugo, M.

Ruiz-Villaverde, R.
License Information

Text and Data Mining valid from 2026-03-01

Text and Data Mining valid from 2026-03-01

Version of Record valid from 2025-12-05
More Information

This article is maintained by: Elsevier

Article Title: RF – Tildrakizumab 200mg. Is Double Dosing Really a Window of Opportunity?

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2025.104539

Content Type: article

Copyright: © 2025 AEDV. Published by Elsevier España, S.L.U.